Search Results
10
Everything
Search Filters
Organization
Immuneering Corporation
Immuneering Corporation Announces Grant of Inducement Award
March 21, 2025 16:30 ET
|
Immuneering Corporation
Immuneering Corporation Announces Grant of Inducement Award
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 20, 2025 16:05 ET
|
Immuneering Corporation
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
March 20, 2025 07:00 ET
|
Immuneering Corporation
IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
February 06, 2025 07:00 ET
|
Immuneering Corporation
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025 16:05 ET
|
Immuneering Corporation
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
January 13, 2025 08:00 ET
|
Immuneering Corporation
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
January 07, 2025 07:00 ET
|
Immuneering Corporation
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104
Immuneering Launches Pancreatic Cancer Advisory Board
December 19, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Launches Pancreatic Cancer Advisory Board
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 17, 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 12, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma